Novo Nordisk is handing its Parkinson's stem cell therapy to a Zuckerberg-backed AI startup

Cellular Intelligence is acquiring STEM-PD, a Phase 2-ready cell therapy, and plans to use AI to accelerate development and manufacturing

SOPA Images / Getty Images

Cellular Intelligence has agreed to acquire Novo Nordisk's experimental Parkinson's disease cell therapy, with the Danish drugmaker taking an equity stake in the Boston-based AI startup as part of the deal.

STEM-PD works by introducing dopamine-producing neurons — grown in a laboratory setting — directly into the brain region where Parkinson's disease causes cell loss. It has received FDA Fast Track Designation and clearance for a Phase 2 trial, the company said. No financial terms were disclosed, though Novo Nordisk will be eligible for milestone payments........

© Quartz